---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-141795"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T05:00:42.633472+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lyell reports LYL314 Phase 1/2 data: 88% ORR, 72% CR in 3L+ LBCL

## Summary
- In efficacy-evaluable 3L+ patients (N=25), ORR 88% (22/25) with 72% CR; median follow-up 9 months.
- 71% (10/14) of CR patients remained in CR at ≥6 months; no Grade ≥3 CRS; no deaths related to LYL314.
- In 2L patients (N=11), ORR 91% with 64% CR; 100% of CR patients in CR at last assessment (3/3 at ≥6 months).
- Plan to initiate randomized pivotal trial of LYL314 in 2L R/R LBCL by early 2026.
- LyFE manufacturing center expected to support >1,200 CAR T doses annually for clinical and early commercial use.

## SEC filing metadata
- accession: 0001193125-25-141795
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000119312525141795/0001193125-25-141795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000119312525141795/d15114d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-141795
- JSON: https://secwatch.observer/filing/0001193125-25-141795.json
- Plain text: https://secwatch.observer/filing/0001193125-25-141795.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.